Full Press Release Details
Coronado Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2012
Burlington, MA August 8, 2012 Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel
immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced its financial results for the second quarter ended June 30, 2012.
Coronado reported a net loss of $6.5 million and $13.0 million for the three and six months ended June 30, 2012, respectively, compared to a net loss of $3.7 million and $26.3 million for the three
and six months ended June 30, 2011, respectively. Included in the net loss for the six months ended June 30, 2011 was a charge of $20.7 million for in-process research and development expense related to the acquisition of TSO (Trichuris
suis ova or CNDO-201). Included in the net loss attributed to common stockholders in the three and six month periods ended June 30, 2011 is $5.9 million fair value of a common stock dividend to the Series A Preferred Stockholders. This
amount is not included in retained deficit.
Research and development expenses were $4.5 million and $9.1 million for the three and six months
ended June 30, 2012, respectively, compared to $2.1 million and $3.4 million for the three and six months ended June 30, 2011, respectively. The increases in research and development expenses relate primarily to the TSO development
General and administrative expenses totaled $1.9 million and $3.9 million for the three and six months ended June 30, 2012,
respectively, compared to $1.6 million and $2.2 million for the three and six months ended June 30, 2011, respectively. The increases in general and administrative expenses included expenses primarily related to the company s
infrastructure growth and increased business activity. At June 30, 2012, Coronado s cash totaled $38.2 million.
quarter, we raised gross proceeds of over $28 million to continue funding the development of our two novel biologic product candidates, TSO and CNDO-109. This capital strengthens our balance sheet and provides sufficient cash into the fourth quarter
of 2013, said Dr. Bobby W. Sandage, Jr., Coronado s President and CEO. Pending discussions with the FDA, we plan to initiate during this quarter a company-sponsored phase 2 clinical trial of TSO for Crohn s disease in
the U.S, which we expect to complete in the second half of 2013. Our partner, Dr. Falk Pharma s phase 2 clinical trial of TSO for Crohn s disease will also have an additional interim analysis in mid-2013. Additionally, we are on
schedule to start screening patients for the phase 1/2 trial of CNDO-109 in acute myeloid leukemia, or AML, before the end of this year.
Recent Corporate and Scientific Highlights:
Conference Call and Webcast Information
Coronado management will review its second quarter financial results and development programs via conference call and webcast today at 8:30 AM ET. To
participate in the conference call, please dial (877) 312-5413 (toll free from the US and Canada), or (253) 237-1511 (for international callers). Investors may also access a live audio webcast of the call at www.coronadobiosciences.com
on the Events & Webcasts page.
A replay of the webcast will be available shortly after the conclusion of the call. The webcast
archive will remain available for one year. An audio replay will also be available shortly after the conclusion of the call and will be made available until August 17, 2012. The audio replay can be accessed by dialing (855) 859-2056 (toll free
from the US and Canada), or (404) 537-3406 (for international callers) and entering Event ID 99614141.
About Coronado Biosciences
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company s two principal pharmaceutical
product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn s disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that
activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors. For more information, please visit www.coronadobiosciences.com.
Forward-Looking Statements
This press release may contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the company s product
development programs and any other statements that are not historical facts. Forward-looking statements are based on management s current expectations and are subject to risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to
preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our
dependence on third party suppliers and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based,
except as required by law.
Contact Information:
Lucy Lu, MD, Executive Vice President & Chief Financial
Coronado Biosciences, Inc.
781-238-6619; ir@coronadobio.com
The Trout Group, LLC.
646-378-2953; tswanson@troutgroup.com
Dennis S. Dobson Jr.,
203-258-0159; dobsonpr@erols.com
CORONADO BIOSCIENCES, INC. AND SUBSIDIARY
(A development stage enterprise)
Consolidated Balance Sheets
| June 30, 2012 | December 31, 2011 | |||||||
| ASSETS | ||||||||
| Cash and cash equivalents | $ | 38,207 | $ | 23,160 | ||||
| Prepaid and other current assets | 286 | 215 | ||||||
| Total Assets | $ | 38,493 | $ | 23,375 | ||||
| LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
| Current liabilities | $ | 3,926 | $ | 3,493 | ||||
| Debt | 750 | 750 | ||||||
| Total Liabilities | 4,676 | 4,243 | ||||||
| Stockholders Equity | 33,817 | 19,132 | ||||||
| Total Liabilities and Stockholders Equity | $ | 38,493 | $ | 23,375 |
CORONADO BIOSCIENCES, INC. AND SUBSIDIARY
(A development stage enterprise)
Consolidated Statements of Operations
($ in thousands except for share
| For the three months ended June 30, | For the six months ended June 30, | |||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 4,525 | $ | 2,142 | $ | 9,116 | $ | 3,388 | ||||||||
| General and administrative | 1,940 | 1,594 | 3,930 | 2,187 | ||||||||||||
| In-process research and development | 20,706 | |||||||||||||||
| Loss from operations | (6,465 | ) | (3,736 | ) | (13,046 | ) | (26,281 | ) | ||||||||
| Interest income | 29 | 22 | 73 | 41 | ||||||||||||
| Interest expense | (19 | ) | (19 | ) | (38 | ) | (36 | ) | ||||||||
| Net loss | (6,455 | ) | (3,733 | ) | (13,011 | ) | (26,276 | ) | ||||||||
| Common Stock dividend to Series A Convertible Preferred Stock | (5,861 | ) | (5,861 | ) | ||||||||||||
| Net loss attributed to Common Stockholders | ($ | 6,455 | ) | ($ | 9,594 | ) | ($ | 13,011 | ) | ($ | 32,137 | ) | ||||
| Basic and diluted net loss per common share | ($ | 0.34 | ) | ($ | 1.64 | ) | ($ | 0.69 | ) | ($ | 6.04 | ) | ||||
| Weighted average common shares outstanding basic and diluted | 19,194,053 | 5,848,642 | 18,899,149 | 5,322,793 |